Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables, has reintroduced Adenosine injection, USP, an antiarrhythmic agent, now in improved prefilled plastic syringes.
According to IMS, for the 12 months ending February 2014, the US market for Adenosine injection, USP approximated $28 million. As with all products in Sagent's portfolio, Adenosine features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
Adenosine injection, USP is indicated for conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration.